Lords Mark Industries Ltd (501261)

Lords Mark Industries has completed its manufacturing capacity expansion at Silvassa ahead of schedule. The company announced it has secured US FDA registration for more than 200 surgical, medical-care, and hygiene products. It plans to commence commercial exports to the United States starting in December 2026, while also exploring South American markets. Specific capex spend and expanded capacity volumes were not disclosed in the filing.

• Completed Silvassa manufacturing capacity expansion ahead of schedule
• Secured US FDA registration for more than 200 surgical, medical-care, and hygiene products
• Commercial exports to the United States slated to begin in December 2026
• Capex quantum and exact capacity figures not disclosed

Lord's Mark Industries has completed the 100% acquisition of Radio Electric Private Limited (known for the 'Radiotone' brand) for a cash consideration of ₹4.50 crore. Founded in 1939, Radio Electric is a debt-free, profitable manufacturer of variable autotransformers and power-control solutions with repeat exports across 7 international markets. The acquisition price is modest relative to Lords Mark's TTM revenue of ₹993 crore (<0.5%), funded entirely via cash. The target's existing manufacturing facility operates at approximately 50% single-shift capacity, offering headroom to support Lords Mark's Battery Energy Storage Systems (BESS) and medical devices divisions.

• 100% equity control acquired in Radio Electric Private Limited for ₹4.50 Cr in cash
• Target is debt-free with an 87-year engineering heritage (founded in 1939)
• Existing manufacturing facility operates at ~50% single-shift capacity, enabling immediate scale-up
• Secures repeat export channels across 7 international markets including Europe, USA, and Canada
• Target client base spans 40-50 domestic blue-chip accounts

Lord's Mark Industries Limited has received registration from the UK's MHRA for its In Vitro Diagnostic (IVD) portfolio, dated September 24, 2026. The approval covers haematological cell analysers, clinical chemistry analysers, diluents, and cleaning agents. Commercial sales in the UK are planned to commence in December 2026, two months ahead of schedule, followed by pathology lab operations starting in January 2027. This follows the company's previous MHRA approval for its AI-powered Renalyx haemodialysis system as it expands in the UK and allied markets.

• MHRA registration received on September 24, 2026, recording the company as a registered manufacturer
• Covers IVD portfolio including haematological cell analysers, clinical chemistry analysers, buffered diluents, and cleaning agents
• UK commercial sales planned to begin in December 2026, approximately 2 months ahead of schedule
• Pathology laboratory operations scheduled to commence in January 2027

Lords Mark Industries announced it has successfully achieved the mandatory 25% Minimum Public Shareholding (MPS) compliance under SEBI Listing Regulations and SCRR rules. This compliance follows the sale of 1,03,56,983 equity shares on September 18, 2026, and an additional 89,98,598 equity shares on September 29, 2026. Prior to this, promoter holding stood at 79.84% as of June 2026, exceeding regulatory limits. The move resolves potential regulatory non-compliance risks and penalties associated with MPS norms.

• Achieved mandatory 25% Minimum Public Shareholding (MPS) requirement
• Sold 1,03,56,983 equity shares on September 18, 2026
• Sold 89,98,598 equity shares on September 29, 2026
• Complied with Rule 19(2)(b) and Rule 19A of SCRR, 1957, and Regulation 38 of SEBI LODR

Lord's Mark Industries announced that its healthcare platform has registered its AI-powered haemodialysis system (developed by Renalyx Health Systems Pvt. Ltd.) with the UK MHRA under GMDN Code 58131. The company plans to start exporting machines to the UK and allied markets from early January 2027, alongside exploring its own dialysis center operations. The MHRA registration serves as device listing but explicitly does not constitute clinical certification or approval by the UK Competent Authority. Against TTM revenue of ₹993 Cr, the commercial financial scale of this development is currently unquantified.

• Registered with the UK MHRA for haemodialysis system under GMDN Code 58131
• Registration covers manufacturer Renalyx Health Systems Pvt. Ltd. for institutional and home use
• Exports to the UK and allied markets scheduled to begin in early January 2027
• MHRA expressly clarifies that this registration does not constitute UK Competent Authority approval or certification

Lords Mark Industries released its Q1 FY27 investor call transcript following its recent reverse-merger listing. The company reported Q1 topline of approximately ₹280 crore and bottomline of ₹32 crore, with 55% revenue contributed by IVD & Medtech and 45% by Renewable Energy. Management disclosed an active renewable energy order book of around ₹3,000 crore and guided for over ₹2,000 crore in annual revenue with 10-11% PAT margins by FY28. To comply with the 75% minimum public shareholding rule, the company is evaluating an OFS, rights issue, or QIP to dilute its current ~80% promoter holding.

• Renewable energy order book stands at approximately ₹3,000 crore
• Targets crossing ₹2,000+ crore revenue with 10-11% PAT margin by FY28
• Q1 FY27 revenue mix was 55% IVD & Medtech (20% EBITDA margin) and 45% Renewable Energy (11% EBITDA margin)
• Planning equity dilution via OFS/rights/QIP to reduce promoter holding from ~80% to 75%
• Dialysis machine commercial production started with Bharat Electronics (BEL) as manufacturing partner